glp-1 and muscle mass loss Nutritional deficiencies in adults with type 2 diabetes using receptor agonists: A retrospective observational study Weight loss with GLP-1 medicines

This unique receptor activity makes tirzepatide a promising candidate for improving bone health in obesity and diabetes, through the positive effects of GIP, and potentially GLP-1, on bone metabolism

These medicines have been extensively examined in Novo Nordisks robust clinical development programs, including randomised controlled trials, which to date have not shown any observable treatment difference compared to placebo for macular degeneration or age-related macular degeneration

Thus, GLP-1RAs play an underlying role in immune-regulation in T1DM (Figure 2)

Certain plans may require documentation of previous attempts to lose weight or evidence of obesity-related health concerns before approving support for GLP-1 therapy

Clear communication ensures safe transitions and supports optimal glycemic control

Orforglipron is the first small-molecule GLP-1 receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial